• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Varian Receives IDE Exemption from FDA to Advance Flash Clinical Research Program

    Enhatch Partners with Holo-Light to Deliver New Extended Reality Streaming Platform

    Study Confirms Safety, Accuracy of Vectorious' V-LAP In-Heart Sensor

    Norman Noble Achieves ISO 13485:2016 Certification

    Indian SMEs Gaining Access to Russian Medtech Market Amid Ukraine Conflict
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Theranos Fraud Trial, Part II: The Blame Game Continues

    An Update on Surgical Robotics

    Letting the Light In: How Failure Analysis is the Cornerstone of Success

    Three Talent Strategies to Attract High-Demand Skills

    The Advantages of Bioburden Screening for Sterilization Validation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    BMP Medical

    JBC Technologies

    Concise Engineering

    Cirtec Medical

    Trademark Plastics Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    ‘Right to Repair’: Separating Fact from Fiction

    Taking a Holistic Approach to Decentralized Clinical Trials (DCTs)

    Investment in Health Startups Drops

    The Power of Leveraging Customer Relationships

    Cost Effective & Efficient Wire EDM Techniques
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    BMP Medical

    JBC Technologies

    Concise Engineering

    Cirtec Medical

    Trademark Plastics Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Top30

    6. Abbott Laboratories

    ...

    Related CONTENT
    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    • FDA Warns of Possible False Positives for Abbott COVID-19 Lab Tests
    • FDA Approves Abbott's Portico with FlexNav TAVR System
    • Abbott Buys Walk Vascular, a Thrombectomy System Maker
    • Hyperfine Welcomes Dave Scott as President and CEO
    07.26.18
    $16.2 Billion ($27.4B total)

    KEY EXECUTIVES:
    Miles D. White, Chairman and CEO
    Brian B. Yoor, Exec. VP, Finance and CFO
    Brian J. Blaser, Exec. VP, Diagnostics Products
    Robert B. Ford, Exec. VP, Medical Devices
    Sharon Bracken, Sr. VP, Rapid Diagnostics
    Chuck Brynelsen, Sr. VP, Abbott Vascular
    Jaime Contreras, Sr. VP, Core Laboratory Diagnostics, Commercial Operations
    Michael J. Pederson, Sr. VP, Cardiac Arrhythmias and Heart Failure
    Jared L. Watkin, Sr. VP, Diabetes Care

    NO. OF EMPLOYEES: 99,000

    GLOBAL HEADQUARTERS: Abbott Park, Ill.

    Wednesday, Jan. 4, 2017, ushered in a new era for Abbott Labs and the medical device industry as a whole. It solidified the largest medtech deal since Medtronic’s $50 billion Covidien buyout, added a bevy of cardiovascular and chronic pain management technologies to Abbott’s arsenal, and constructed a brand new medical device behemoth.

    According to the Chicago Tribune, since integrating Minnesota-based St. Jude Medical Inc., cardiovascular and chronic pain devices now comprise about a third of Abbott’s total business. Prior to that, cardiovascular technologies made up approximately 15 percent of the business, and the chronic pain management segment didn’t exist at all. In fact, 2017 revenue from the chronic pain management and cardiovascular sales alone—about $8.9 billion—would have been enough to earn it a spot in the Top 30.

    But with $16.2 billion in fiscal 2017 medical device and diagnostics sales (year ended Dec. 31), Abbott surged ahead several spots in the list. Chiefly thanks to the full integration of St. Jude, the Illinois-based firm’s medical device earnings jumped an earth-shattering 60.4 percent over the previous year. To fully realize the sale’s tremendous impact, Medtronic’s integration of Covidien netted it a 42.3 percent payoff boost—especially impactful considering the $25 billion St. Jude deal was half the price.

    Absorbing St. Jude didn’t come without a price to Abbott, however. The Federal Trade Commission only gave its consent to  the deal after Abbott agreed to sell its business focused on steerable sheaths—which are used to guide catheters in treating heart arrhythmias—and St. Jude’s vascular closure device business to Tokyo-based medical device maker Terumo Corp.

    Less than a week after the deal closed, the FDA also confirmed that St. Jude’s implantable cardiac devices contained vulnerabilities that could permit hackers to access a device. Once in, the agency warned that intruders might be able to deplete the battery or administer incorrect pacing or shocks.

    The potential for vulnerability was already in the public mind as early as August 2016, when investment firm Muddy Waters founder Carson Block released a report claiming St. Jude’s devices could be tampered with. At the time, St. Jude said the claims were “absolutely untrue” and subsequently filed a lawsuit against the firm.

    Block told CNN Tech the FDA’s announcement “vindicates” his firm’s research. St. Jude also developed a software patch in response to the issue to fix the vulnerabilities, but Block was still skeptical.

    “It also reaffirms our belief that had we not gone public, St. Jude would not have remediated the vulnerabilities,” he said. “Regardless, the announced fixes do not appear to address many of the larger problems, including the existence of a universal code that could allow hackers to control the implants.”

    Abbott finally remediated the issue late last August, following an FDA approval for a software update earlier that month. The update included a battery performance alert for implantable cardioverter defibrillators (ICDs) that warns physicians about the risk of premature battery depletion earlier. According to the Tribune, as of October 2016, two people had died in incidents associated with the devices. Further, as of that date, 841 out of nearly 400,000 devices experienced the early battery depletion.

    Though the FDA found no instances of patient harm resulting from the cybersecurity issue, Abbott also released a planned update to pacemaker firmware that added additional security protections to reduce the risk of unauthorized access.

    “All industries need to be constantly vigilant against unauthorized access,” Robert Ford, Abbott’s executive vice president of medical devices, commented regarding the update. “This isn’t a static process, which is why we’re working with others in the healthcare sector to ensure we’re proactively addressing common topics to further advance the security of devices and systems.”

    And in the midst of all of this, Abbott was still embroiled in the tumultuous deal to purchase Massachusetts-based point-of-care (POC) diagnostics firm Alere. Those following the acquisition’s sordid history may recall that Abbott had previously attempted to back out of the deal after a slew of financial and ethical missteps that came to light during negotiations. This led to lawsuits filed from both companies, with Alere forcing Abbott to move ahead with the deal, and Abbott wanting to back out, citing “substantial loss” in the diagnostic company’s value.

    Rather than abandoning the deal, last April Abbott instead offered to purchase Alere at about $5.3 billion, $500 million down from the original purchase price—and Alere agreed. Abbott ended up paying $51 per share for the company, a far better outcome than what Alere’s shareholders had priced in—according to Reuters, Alere’s shares closed at $42.31 the day before the offer was made.

    “The renegotiated price is in the realm of investor expectations and seems to reflect the impact from some of the challenges witnessed in Alere’s business over the last 12 months,” Raymond James analyst Nicholas Jansen told Reuters.

    After nearly 20 months of negotiations, Abbott finally closed the deal for Alere early last October. The transaction made the company a leading force in the POC testing market, the fastest growing segment of the $50 billion in-vitro diagnostics (IVD) market. According to Abbott, the POC testing market was valued at $7 billion in 2016, and is growing quickly as physicians increasingly adopt rapid tests that speed up treatment. POC tests provide results to doctors in minutes and can be conducted in the physician’s office, an ambulance, or at home.

    Abbott’s diagnostics business produces core laboratory, molecular, and POC diagnostics, in addition to rapid diagnostics offerings obtained through buying Alere. Last year, the business accrued $5.6 billion in revenue, rising a respectable 16.7 percent primarily due to the addition of Alere’s portfolio in the fourth quarter, which touted $540 million in sales. Meanwhile, core laboratory sales rose 6 percent to $4.1 billion, molecular diagnostics stepped up 2 percent to $463 million, and POC diagnostics increased 7 percent to $550 million. Continued adoption of the i-STAT handheld system and share gains in the global core laboratory and POC markets were also significant drivers of revenue expansion for this business.

    A week after closing the St. Jude deal, Abbott gained CE mark clearance for its Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics. The next generation of harmonized systems aim to help labs and hospital systems run more tests in less time, reduce human error, and increase testing productivity. With a flexible, modular design, the Alinity c clinical chemistry system and Alinity i immunoassay system can operate individually or as an integrated Alinity ci-series unit, all within half the size of typical diagnostics systems. The system features increased loading capacity for samples and tests, continuous access to solutions and supplies, error-proof design elements, and an intuitive menu design with a user-friendly interface. The Alinity ci-series instruments also received FDA clearance last Halloween.

    The same day the Alinity ci-series instruments hit the European market, Abbott also obtained EU approval for the Alinity s System for blood and plasma screening. The new system screens blood and plasma faster, more efficiently, and within a smaller footprint than Abbott’s current solutions. Alinity s can run up to 600 tests per hour and boosts walk-away time to a minimum of three hours. Further, it allows lab professionals the option to continuously load and unload samples and supplies without pausing or stopping the system.

    Last February, the FDA authorized Abbott’s RealTime ZIKA molecular test to detect Zika virus in whole blood when collected alongside a patient-matched serum or plasma sample for emergency use. It marked the first molecular test made by a commercial manufacturer authorized to detect Zika in whole blood samples, which is significant because Zika can be detected in whole blood for longer (up to two months) and at higher levels than testing with serum and urine samples. The test generates results in five to seven hours and is also automated, so lab professionals can spend less time preparing and handling samples.

    The Alinity hq analyzer for hematology achieved CE mark approval last June. Hematology studies the physiology of blood and the cause, diagnosis, treatment, and prevention of blood-related diseases. Hematology tests examine blood composition by identifying and quantifying different types of blood cells. The Alinity hq analyzer automates these tests and reports on 29 different parameters within minutes. It does so via advanced optical technology combined with algorithms to handle normal and pathological samples, and a scalable, modular design to customize configurations to better serve a broad array of labs.

    The same day, Abbott procured CE mark clearance for the Sekisui CP3000 coagulation system, an automated analyzer that tests bleeding and clotting function in blood. Abbott’s AlinIQ informatics and service offerings streamline operations, providing intelligent lab insights and simplifying reading and interpretation of results. Further, the CP3000 coagulation system can automate and standardize sample management and flag unsuitable samples at the start of testing. It offers an expanded menu of barcoded reagents to reduce data entry errors. All of these functions work together to curb delays in coagulation testing related to sample errors and manual errors in the testing process.

    Abbott’s cardiovascular and neuromodulation portfolio consists of remaining vascular and structural heart products not divested to Terumo, as well as rhythm management, electrophysiology, heart failure, and neuromodulation technologies obtained through the St. Jude purchase. This segment expectedly benefitted from the most significant revenue bump due to the deal—in 2017, the business generated $8.9 billion in sales, approximately tripling in revenue from the year prior.

    The rhythm management, electrophysiology, heart failure, and neuromodulation product lines acquired from St. Jude exhibited $2.1 billion, $1.4 billion, $643 million, and $808 million in 2017 revenue respectively. The vascular portfolio rose 14 percent to achieve $2.9 billion in proceeds, and the structural heart segment ballooned 208 percent to earn $1.1 billion in sales.

    Abbott launched the EnSite Precision cardiac mapping system and Advisor FL Circular Mapping Catheter to map cardiac arrhythmias during ablation treatments last January. Built on the foundation of St. Jude’s cardiac mapping technology, EnSite Precision lends automation, flexibility, and precision to cardiac mapping. The dual-technology platform leverages detailed anatomical models and maps to treat a wider range of arrhythmias, including atrial fibrillation and ventricular tachycardia. The system’s EnSite AutoMap module helps electrophysiologists more quickly perform morphology matching to identify the source of the irregular heartbeat. The TurboMap feature included within the module also allows physicians to construct heart maps 10 times faster than current systems using recorded data.

    A week later, the Proclaim DRG (dorsal root ganglion) Neurostimulation system for chronic neuropathic pain was launched in Europe. Neuropathic pain is one of the most prevalent, yet undertreated forms of chronic pain. The device targets nerves within the DRG, which is a spinal structure rife with sensory nerves. By stimulating this area, Proclaim DRG can help patients manage difficult-to-treat chronic pain in the foot, knee, hip, or groin. Abbott’s ACCURATE study of Proclaim DRG also demonstrated that DRG therapy can offer superior pain relief for patients with complex regional pain syndrome and other focal chronic neuropathic pain conditions, as compared to traditional spinal cord stimulation technology.

    “Many patients battling chronic neuropathic pain have not found adequate relief from other forms of treatment, which is why dorsal root ganglion stimulation has been such an important therapeutic advancement for pain specialists worldwide,” said Harold Nijhuis, M.D., an anesthesiologist from St. Antonius Ziekenhuis, Niuwegein, the Netherlands. “With the approval of the Proclaim DRG System, I am able to address chronic focal pain for my patients while offering them access to new, patient-centric benefits and features to improve their therapy experience.”

    The Assurity MRI pacemaker and Tendril MRI pacing lead won FDA approval for MR-conditional labeling at the start of February 2017, granting patients implanted with the low-voltage devices the ability to undergo full-body MRI scans. The world’s smallest, longest lasting wireless MRI-compatible pacemaker can also wirelessly and remotely monitor the patient so physicians can securely access diagnostic metrics and daily device measurements. Assurity MRI also uses a handheld device to trigger pre-programmed MRI settings tailored to individual patients, eliminating the effort, time, and inconvenience of conventional pre- and post-scan reprogramming.

    Abbott obtained FDA approval for the FlexAbility Ablation Catheter, Sensor Enabled a month later. Expanding the company’s electrophysiology portfolio for patients suffering from cardiac arrhythmias, the ablation catheter helps collect both impedance and magnetic data for detailed, accurate mapping and to assist in treating sites triggering or sustaining abnormal heart rhythms. FlexAbility was the second Sensor Enabled tool released in the United States for the EnSite system, and allows physicians to create highly detailed 3D cardiac models with the heart’s electrical activity overlaid on it.

    Last May, the Confirm Rx Insertable Cardiac Monitor (ICM), the world’s first smartphone compatible ICM, was awarded CE mark approval. The Confirm Rx ICM continuously monitors heart rhythm and transmits information to the myMerlin mobile app so physicians can follow patients remotely and accurately diagnose arrhythmias. The ICM directly and securely communicates to the app downloaded onto a patient’s smartphone. Traditionally, remote monitoring has required bulky handheld or bedside transmitters, limiting patient mobility. Further, the device is slimmer than currently available ICMs, and touts one-touch indication-based programming to make the technology more convenient. The Confirm Rx ICM made its U.S. debut last October.

    “The Confirm Rx ICM device will be an important tool for diagnosing patients with suspected arrhythmias, such as those who have experienced fainting or palpitations,” said Georg Nölker, M.D., head of electrophysiology at the Herz-und Diabeteszentrum NRW, Ruhr-University of Bad Oeynhausen, Germany. Dr. Nölker was one of the first physicians to implant the Confirm Rx ICM after it received CE mark clearance. “The simple insertion procedure and small device size make this technology convenient for both patients and providers. Patients can record symptoms directly on their smartphone without the need for a bedside transmitter or separate activator.”

    A week later, the TactiCath Contact Force Ablation Catheter, Sensor Enabled, the latest catheter for use with the EnSite Precision system, gained EU approval. Like its predecessor, TactiCath provides dual impedance and magnetic technologies to more precisely model the heart. However, the integrated system also helps physicians determine where to apply optimal contact force (pressure) when creating a lesion during a cardiac ablation to correct a heart rhythm abnormality.

    In August, Abbott began the TRILUMINATE study, a prospective, single-arm, multi-center study designed to evaluate the performance of clip-based technology in approximately 75 symptomatic moderate or severe tricuspid regurgitation patients at 25 sites across the United States and Europe. The transcatheter tricuspid valve repair system builds on Abbott’s more than a decade of development for the MitraClip system for mitral regurgitation. TRILUMINATE is the first trial of its kind to evaluate minimally invasive treatment using clip technology for moderate or severe tricuspid regurgitation.

    Toward the end of last August, Abbott achieved an FDA nod for the Full MagLev HeartMate 3 Left Ventricular Assist System (LVAD). HeartMate 3 offered physicians a new option to manage advanced heart failure patients needing bridge-to-transplant or bridge to myocardial recovery. HeartMate 3’s pump uses magnetic levitation (the only LVAD of its kind to do so), which helps to reduce trauma to blood passing through the system. The “Full MagLev” technology allows the device’s rotor to be “suspended” by magnetic forces rather than bearings to more gently pass blood cells trough the pump, no matter what speed settings are used by the physician. It can pump up to 10 liters of blood per minute, and relies on a built-in “pulse,” which is programmed to ensure blood continues to move through without becoming static, reducing the risk of blood clots.

    This past May, however, Abbott recalled all lots of HeartMate 3 due to a malfunction in the device’s outflow graft assembly that may cause the outflow graft to twist and close up (occlusion) over time.

    Last September, the Ellipse ICD with Tendril MRI pacing lead and Durata and Optisure high voltage leads obtained FDA approval for MR-conditional labeling. Ellipse, according to Abbott, is one of the company’s most widely used ICDs and associated high-voltage leads.

    Xience Sierra, the newest generation of Abbott’s Xience everolimus-eluting coronary stent system, received CE mark approval last October. Xience Sierra boosts cardiologists’ ability to access and unblock difficult-to-reach lesions thanks to a new stent design and delivery system and unique size options.

    Abbott’s remaining medical device revenue is encompassed in the “Other” category, which since the sale of Abbott Medical Optics to J&J in 2016 consists entirely of Diabetes Care products. The segment—which will presumably be named Diabetes Care in next year’s report—reported $1.7 billion in revenue.

    However, Diabetes Care released what was perhaps Abbott’s most momentous device of the year. Last September, the FreeStyle Libre Flash Glucose Monitoring System won FDA approval for adults. Consisting of a sensor about the size of a quarter worn on the back of the upper arm, the device was the first continuous glucose monitor (CGM) that doesn’t require diabetics to routinely prick their fingers, even for calibration. Patients place a handheld reader near the device to see current glucose levels, trends, patterns, and where their levels may be headed. Those readings can help patients determine how much insulin to take to manage their diabetes.

    At the time of release, national health insurance systems in 18 countries—including the U.K., France, Germany, and Japan—agreed to partially cover the CGMs. Two months after the approval, FreeStyle Libre CGM entered the shelves of U.S. pharmacies. And as of January 2018, the device received coverage for Medicare patients with diabetes who use insulin and meet the eligibility criteria.

    “The accessibility and affordability of this CGM technology is unprecedented, and this is a huge step forward for the diabetes community—both Type 1 and Type 2,” said George Grunberger, M.D., chairman of the Grunberger Diabetes Institute. “More importantly, the evidence of FreeStyle Libre being used in the real world shows how people are getting better insights into their glucose levels with this product and achieving better glycemic control—that’s something that you can’t put a price to.”

    Last July, Abbott also began a collaboration to develop breakthrough diabetes technologies with Bigfoot Biomedical, a Milpitas, Calif.-based insulin delivery service firm that seeks to improve the lives of diabetics through the application of smart technology that leverages data, connectivity, automation, and machine learning. Under the agreement, Abbott will supply glucose measurement sensors for all of Bigfoot’s insulin delivery systems in the United States as the exclusive sensors for those systems. Bigfoot will develop and commercialize multiple systems using Abbott’s FreeStyle Libre CGM, including systems designed to perform auto-titration for Bigfoot’s connected insulin injection devices, as well as automated insulin delivery using Bigfoot’s insulin infusion platform.
    Related Searches
    • traditional spinal cord stimulation
    • ford
    • medtronic
    • medicare
    Suggested For You
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    FDA Warns of Possible False Positives for Abbott COVID-19 Lab Tests FDA Warns of Possible False Positives for Abbott COVID-19 Lab Tests
    FDA Approves Abbott FDA Approves Abbott's Portico with FlexNav TAVR System
    Abbott Buys Walk Vascular, a Thrombectomy System Maker Abbott Buys Walk Vascular, a Thrombectomy System Maker
    Hyperfine Welcomes Dave Scott as President and CEO Hyperfine Welcomes Dave Scott as President and CEO
    FDA OKs Abbott FDA OKs Abbott's AI OCT Imaging for Vessels in the Heart
    Abbott Fined $160M to Resolve Medicare Diabetes Lawsuit Abbott Fined $160M to Resolve Medicare Diabetes Lawsuit
    FDA OKs Abbott FDA OKs Abbott's FreeStyle Libre 2 iOS App
    Abbott Rolls Out Jot Dx Insertable Cardiac Monitor Abbott Rolls Out Jot Dx Insertable Cardiac Monitor
    Catheter and Medical Design Hires Two Industry Experts Catheter and Medical Design Hires Two Industry Experts
    Global Enteral Feeding Devices Market to Reach $4.85 Billion by 2027 Global Enteral Feeding Devices Market to Reach $4.85 Billion by 2027
    The Reemergence of Pulsed Field Ablation in Cardiac Electrophysiology The Reemergence of Pulsed Field Ablation in Cardiac Electrophysiology
    Abbott Abbott's Panbio Rapid COVID-19 Antigen Self-Test Earns EU Approval
    Expanded FDA Approval for Medtronic Expanded FDA Approval for Medtronic's Arctic Front Cryoablation Catheter
    Abbott Engages in STEM Internships for College Credit Abbott Engages in STEM Internships for College Credit

    Related Breaking News

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21

    • Diagnostics
      FDA Warns of Possible False Positives for Abbott COVID-19 Lab Tests

      FDA Warns of Possible False Positives for Abbott COVID-19 Lab Tests

      May be related to current mixing parameters of the PCR reaction mixture.
      U.S. Food and Drug Administration 09.20.21

    • Cardiovascular
      FDA Approves Abbott

      FDA Approves Abbott's Portico with FlexNav TAVR System

      Self-expanding TAVR valve features intra-annular (within the native valve) leaflets.
      PR Newswire 09.20.21


    • Cardiovascular
      Abbott Buys Walk Vascular, a Thrombectomy System Maker

      Abbott Buys Walk Vascular, a Thrombectomy System Maker

      Adds mechanical thrombectomy devices for treating patients with peripheral blood clots.
      PR Newswire 09.02.21

    • Hyperfine Welcomes Dave Scott as President and CEO

      Hyperfine Welcomes Dave Scott as President and CEO

      New leader worked for Apple, Google (Verb Surgical), and led the design team for Intuitive Surgical's visualization platform.
      Business Wire 08.23.21

    Loading, Please Wait..

    Trending
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • FDA OKs J&J Vision's AcuVue Oasys Max 1-Day Contact Lenses
    • How To Overcome The Top 6 Medical Device Manufacturing Challenges
    • Cepheid, BioGX Partner To Create GeneXpert Monkeypox Test
    • Intermountain Healthcare & Siemens Healthineers Open 3 Tellica Outpatient Imaging Centers
    Breaking News
    • Varian Receives IDE Exemption from FDA to Advance Flash Clinical Research Program
    • Enhatch Partners with Holo-Light to Deliver New Extended Reality Streaming Platform
    • Study Confirms Safety, Accuracy of Vectorious' V-LAP In-Heart Sensor
    • Norman Noble Achieves ISO 13485:2016 Certification
    • Indian SMEs Gaining Access to Russian Medtech Market Amid Ukraine Conflict
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • OEMs Seek Molders Offering Timely Techniques
    • Robotic Surgery: Cutting Through to the Latest
    • Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kensing Acquires Vitae Naturals
    CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise
    Shiitake Mushroom Extract Appears Helpful in HPV Infections
    Coatings World

    Latest Breaking News From Coatings World

    PPG to Increase U.S. Aerospace Products Manufacturing Output to Meet Rising Demand
    Solvay to Discontinue Use of Fluorosurfactants for Production of Fluoropolymers
    AkzoNobel Names New CEO
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Varian Receives IDE Exemption from FDA to Advance Flash Clinical Research Program
    Enhatch Partners with Holo-Light to Deliver New Extended Reality Streaming Platform
    Study Confirms Safety, Accuracy of Vectorious' V-LAP In-Heart Sensor
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Shimadzu Scientific Instruments Extends HQ Campus
    Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
    Batavia Enters Commercial Manufacturing Business
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Naples Soap Company to Open New Store in Venice, Florida
    Nectar Recruits 8-Year-Old YouTube Star to Launch Her Own Bath & Body Line
    L'Oreal Exec Joins Function of Beauty
    Happi

    Latest Breaking News From Happi

    Rhode Island’s Department of Health, Raw Elements and Partners Expand Touch-Free Mineral Sunscreen
    Julee Wilson Named Executive Director of BeautyUnited
    Arey Launches Unisex Leave-In Conditioner
    Ink World

    Latest Breaking News From Ink World

    Amcor Lift-Off Initiative Shortlists Start-ups for Seed Funding
    Barentz Highlights Lincoln MFG’s New ISO 9001:2015 Certification
    Ingevity Appoints Christine Stunyo as Chief Human Resources Officer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood introduces Sitexco Label L10 anilox cleaning system
    Germark makes double press investment in Bobst
    UPM Raflatac to enhance service capabilities at Mills River factory
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Rockline's Springdale Campus Achieves 15 Million Safe Work Hours
    Emmanuelle Picard to Join Ahlstrom-Munksjö's Executive Management Team
    Alkegen Completes Luyang Acquisition
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Researchers Develop Microfluidic Sensors to Improve Implant Survival Rates
    Lawrence Yellin Appointed as Fuse Medical CFO
    Researchers Discover Novel Patching Material for Bone Defects
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Avery Dennison Highlights New Approach to Apparel with ADX Lab
    trinamiX Face Authentication Protects Users from Fraud Attacks During Mobile Payments
    Hugo Boss Partners with Nedap for Global RFID Roll-out

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login